Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













BI 224436






●Српски / srpski
 ●Srpskohrvatski / српскохрватски
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

BI 224436

Clinical data

ATC code

  • none

Legal status

Legal status

  • Investigational

Pharmacokinetic data

Elimination half-life

7 hrs (simulated)[1]

Identifiers

  • (2S)-[4-(2,3-Dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methyl-3-quinolinyl] [(2-methyl-2-propanyl)oxy]acetic acid

CAS Number

PubChem CID

ChemSpider

UNII

CompTox Dashboard (EPA)

Chemical and physical data

Formula

C27H26N2O4

Molar mass

442.515 g·mol−1

3D model (JSmol)

  • CC1=NC2=CC=CC=C2C(=C1[C@@H](C(=O)O)OC(C)(C)C)C3=C4C5=C(C=C3)OCCC5=CC=N4

  • InChI=1S/C27H26N2O4/c1-15-21(25(26(30)31)33-27(2,3)4)23(17-7-5-6-8-19(17)29-15)18-9-10-20-22-16(12-14-32-20)11-13-28-24(18)22/h5-11,13,25H,12,14H2,1-4H3,(H,30,31)/t25-/m0/s1

  • Key:MIXIIJCBELCMCZ-VWLOTQADSA-N

    • BI 224436 was an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in its mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.[2] In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.[3][4]

    Clinical trials were abandoned in advance of Phase 1.[5]

    References[edit]

    1. ^ Brown A, McSharry J, Kulawy R (17 September 2011). Pharmacodynamics of BI 224436 for HIV-1 in an in vitro hollow fiber infection model system. 51st Interscience conference on antimicrobial agents and chemotherapy. Chicago. pp. 17–20.
  • ^ Fenwick C, Bethell R, Cordingley M, Edwards P, Quinson AM, Robinson P, Simoneau B, Yoakim C (17 September 2011). Levin J (ed.). BI 224436, a non-catalytic site integrase inhibitor, is a potent inhibitor of the replication of treatment-naïve and raltegravir-resistant clinical isolates of HIV-1. 51st Interscience Conference on Antimicrobials and Chemotherapy. Chicago: ICAAC.
  • ^ "Gilead Negotiates Worldwide License to BI's Early Clinical Stage HIV Program". Genetic Engineering and Biotechnology News. 6 October 2011. Archived from the original on 23 January 2013.
  • ^ Highleyman L (7 October 2011). "ICAAC: New Integrase Inhibitor BI 224436 Active against Raltegravir-Resistant HIV". HIVandHepatitis.com.
  • ^ Clinical trial number NCT01276990 for "Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers." at ClinicalTrials.gov
    • Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

    Capsid inhibitors

    Entry/fusion inhibitors
    (Discovery and development)

  • CCR5 (Maraviroc (MVC)
  • Vicriviroc†, Cenicriviroc†, Leronlimab†)
  • CD4 (Ibalizumab (IBA), Semzuvolimab§)
  • gp120 (Fostemsavir (FTR))

    • Integrase inhibitors
    (Integrase strand transfer inhibitors (INSTI))

  • Cabotegravir (CAB)
  • Dolutegravir (DTG)#
  • Elvitegravir (EVG)
  • Raltegravir (RAL)#
  • BI 224436†
  • MK-2048†

    • Maturation inhibitors

  • BMS-955176§
  • Fipravirimat§

    • Protease Inhibitors (PI)
    (Discovery and development)

    1st generation

  • Fosamprenavir (FPV)
  • Indinavir (IDV)◊
  • Lopinavir (LPV)
  • Nelfinavir (NFV)◊
  • Ritonavir (RTV)#
  • Saquinavir (SQV)◊

    • 2nd generation

  • Darunavir (DRV)°#
  • Tipranavir (TPV)◊
  • TMC-310911§

    • Reverse-transcriptase
    inhibitors     (RTIs)

    Nucleoside and
    nucleotide (NRTI)

  • Didanosine (ddI)◊
  • Emtricitabine (FTC)
  • Lamivudine (3TC)#
  • Stavudine (d4T)◊
  • Zalcitabine (ddC)‡
  • Zidovudine (AZT, ZDV)#
  • Amdoxovir†
  • Apricitabine†
  • Censavudine†
  • Elvucitabine†
  • Islatravir (EFdA, ISL)§
  • Racivir†
  • Stampidine†

    • Non-nucleoside (NNRTI)
    (Discovery and development)

    1st generation

  • Nevirapine (NVP)#
  • Delavirdine (DLV)‡

    • 2nd generation

  • Etravirine (ETR)
  • Rilpivirine (RPV)
  • Doravirine (DOR)
  • Elsulfavirine (ESV)

    • Combined formulations

  • Abacavir/dolutegravir/lamivudine°
  • Abacavir/lamivudine/zidovudine
  • Atazanavir/cobicistat
  • Bictegravir/emtricitabine/tenofovir alafenamide°
  • Cabotegravir/rilpivirine
  • Darunavir/cobicistat
  • Darunavir/cobicistat/emtricitabine/tenofovir alafenamide°
  • Dolutegravir/emtricitabine/tenofovir alafenamide
  • Dolutegravir/lamivudine°
  • Dolutegravir/lamivudine/tenofovir alafenamide°
  • Dolutegravir/lamivudine/tenofovir disoproxil°#
  • Dolutegravir/rilpivirine
  • Doravirine/lamivudine/tenofovir disoproxil
  • Efavirenz/emtricitabine/tenofovir disoproxil#
  • Efavirenz/lamivudine/tenofovir disoproxil#
  • Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
  • Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
  • Emtricitabine/tenofovir alafenamide
  • Emtricitabine/rilpivirine/tenofovir alafenamide
  • Emtricitabine/rilpivirine/tenofovir disoproxil
  • Emtricitabine/tenofovir disoproxil#
  • Lamivudine/nevirapine/stavudine
  • Lamivudine/nevirapine/zidovudine
  • Lamivudine/raltegravir
  • Lamivudine/tenofovir disoproxil#
  • Lamivudine/zidovudine#
  • Lopinavir/ritonavir#

    • Pharmacokinetic boosters

  • Ritonavir (r)#

    • Experimental agents

    Uncoating inhibitors

    Transcription inhibitors

    Translation inhibitors

    BNAbs

    Other

  • BIT225†
  • Calanolide A
  • Ceragenin
  • Cyanovirin-N
  • Diarylpyrimidines
  • Epigallocatechin gallate (EGCG)
  • Foscarnet
  • Fosdevirine†
  • Griffithsin
  • Hydroxycarbamide
  • KP-1461†
  • Miltefosine
  • Portmanteau inhibitors
  • Scytovirin
  • Seliciclib†
  • Synergistic enhancers
  • Tre recombinase
  • Zinc finger protein transcription factor

    • Failed agents

  • Atevirdine
  • Brecanavir
  • Capravirine
  • Dexelvucitabine
  • Droxinavir
  • Lasinavir
  • Emivirine
  • Lersivirine
  • Lodenosine
  • Loviride
  • Mozenavir
  • Palinavir
  • Telinavir

  • ‡Withdrawn from market
  • Clinical trials:
  • §Never to phase III
    • °DHHS recommended initial regimen options. ◊Formerly or rarely used agent.


    Stub icon

    This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=BI_224436&oldid=1187850092"
    Categories: 
    ●Drugs not assigned an ATC code
     ●Integrase inhibitors
     ●Experimental antiviral drugs
     ●Tert-butyl compounds
     ●Antiinfective agent stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Drugs with non-standard legal status
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles containing unverified chemical infoboxes
     ●All stub articles
      


    ●This page was last edited on 1 December 2023, at 20:41 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki